These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 19038418

  • 1. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME, Black KL, Bauman ML, Belletrutti M, Bajzar L, Massicotte MP.
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [Abstract] [Full Text] [Related]

  • 2. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS.
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [Abstract] [Full Text] [Related]

  • 3. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA, Gurian M, Hegyi T, Drachtman RA.
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
    Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P.
    Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
    [Abstract] [Full Text] [Related]

  • 6. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK, Shelton CM, Sahni JK, Christensen ML.
    Ann Pharmacother; 2012 Jun; 46(7-8):943-51. PubMed ID: 22828970
    [Abstract] [Full Text] [Related]

  • 7. Experience with intravenous enoxaparin in critically ill infants and children.
    Crary SE, Van Orden H, Journeycake JM.
    Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932
    [Abstract] [Full Text] [Related]

  • 8. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D.
    Circulation; 2004 Jul 27; 110(4):392-8. PubMed ID: 15249498
    [Abstract] [Full Text] [Related]

  • 9. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H, Faraklas I, Saffle J, Cochran A.
    J Trauma; 2011 Dec 27; 71(6):1557-61. PubMed ID: 22027887
    [Abstract] [Full Text] [Related]

  • 10. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM, Jackevicius CA, Yeo E.
    Ann Pharmacother; 2004 Oct 27; 38(10):1576-81. PubMed ID: 15328396
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Variability of plasma anti-Xa activities with different lots of enoxaparin.
    Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT.
    Ann Pharmacother; 2004 Apr 27; 38(4):563-8. PubMed ID: 14982983
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S, Lemos PA, Esteves A, Ribeiro EE, Horta P, Nicolau JC, Ramires JA, Cohen M, Martinez EE.
    J Invasive Cardiol; 2006 Feb 27; 18(2):45-8. PubMed ID: 16446514
    [Abstract] [Full Text] [Related]

  • 16. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD, Lakhani M, El Rouby S, Cavusoglu E.
    J Invasive Cardiol; 2008 Sep 27; 20(9):449-54. PubMed ID: 18762674
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA, Kim S, Moffett BS, Bomgaars L, Mahoney D, Yee DL.
    J Pediatr; 2013 Feb 27; 162(2):293-6. PubMed ID: 22959138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.